Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Biological: Bevacizumab
Drug: Cisplatin
Drug: Fluorouracil
Radiation: Intensity-Modulated Radiation Therapy

First Posted Date: 2006-12-07

Last Posted Date: 2018-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00408694

Locations: 🇺🇸
AnMed Health Hospital, Anderson, South Carolina, United States
🇺🇸
Rutgers New Jersey Medical School, Newark, New Jersey, United States
🇺🇸
UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

and more 105 locations

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Neoplasms

First Posted Date: 2006-11-22

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00402545

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma
Oral Cancer

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: 5-fluorouracil

First Posted Date: 2006-11-16

Last Posted Date: 2017-11-06

Lead Sponsor: Emory University

Target Recruit Count: 14

Registration Number: NCT00400205

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Paclitaxel
Drug: 5-FU
Radiation: Radiation Therapy

First Posted Date: 2006-10-26

Last Posted Date: 2013-02-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00392704

Locations: 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 4 locations

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Erlotinib
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5-FU
Procedure: Radiation therapy
Procedure: Surgery

First Posted Date: 2006-10-26

Last Posted Date: 2022-03-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT00393068

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Phase 2

Withdrawn

Conditions: Cancer of the Bile Duct
Gallbladder Cancer

Interventions: Drug: GM-CT-01
Drug: 5-Fluorouracil

First Posted Date: 2006-10-11

Last Posted Date: 2017-08-01

Lead Sponsor: Galectin Therapeutics Inc.

Registration Number: NCT00386516

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Barrett Cancer Center, Cincinnati, Ohio, United States
🇺🇸
University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Phase 2

Completed

Conditions: Colorectal Cancer
Nausea and Vomiting

Interventions: Drug: aprepitant
Drug: dexamethasone
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: palonosetron hydrochloride
Procedure: quality-of-life assessment

First Posted Date: 2006-09-28

Last Posted Date: 2017-06-12

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00381862

Locations: 🇺🇸
St. Josephs/Cander Hospital, Savannah, Georgia, United States
🇺🇸
Kaiser Permanente, Hilo, Hawaii, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 3 locations

Combination Chemotherapy in Treating Patients With Resected Colon Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-fluorouracil
Drug: tegafur
Drug: leucovorin calcium
Drug: uracil

First Posted Date: 2006-09-21

Last Posted Date: 2010-01-11

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 1608

Registration Number: NCT00378716

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Leucovorin
Drug: Irinotecan

First Posted Date: 2006-07-20

Last Posted Date: 2011-10-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00354978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: fluorouracil
Drug: Iressa
Radiation: hyperfractionated radiation therapy

First Posted Date: 2006-07-14

Last Posted Date: 2012-11-04

Lead Sponsor: David Adelstein

Target Recruit Count: 60

Registration Number: NCT00352105

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy